NEWARK, DE / ACCESSWIRE / June 1, 2023 / The global APOL1 Mediated Kidney Disease Market is anticipated to attain a valuation of US$ 3779.9 million in 2023 and is expected to reach US$ 5753.9 million by 2033, trailing a CAGR of 4.3% during the projected forecast period.
The approval of new drugs in the chronic kidney disease market has multiple benefits. It provides healthcare providers and patients with more treatment options, leading to revenue growth for pharmaceutical companies. It also improves patient access to treatment and encourages ongoing research and development in the field. Furthermore, the high regulatory standards set for new treatments ensure their safety and effectiveness. These factors contribute to the expected growth of the Chronic Kidney Disease Market in the forecast period.
Get your PDF Sample report with Latest Market Insights @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12115
The market is expected to be fuelled by factors such as the rising prevalence of chronic kidney disease worldwide. The increasing demand for novel treatments to enhance patients' quality of life is driven by the growing incidence of chronic kidney diseases. According to a 2019 report from the Centers for Disease Control and Prevention, approximately 37 million people in the United States are estimated to have chronic kidney diseases.
The increasing geriatric population, which is susceptible to various diseases including APOL 1 mediated kidney diseases, is a major driver for market growth. Hence, increasing research and development activities in the development of chronic kidney disease drugs are expected to generate new opportunities for market expansion during the forecast period.
AstraZeneca sealed a $330 million licensing agreement in 2018 with Ionis Pharmaceuticals, Inc., a clinical-stage innovator company focused on advanced research for rare diseases based in the United States. This agreement encompassed two pipeline antisense therapies. Notably, one of the licensed therapeutics is an investigational novel antisense drug called AZD2373, designed to target the root cause of APOL1 mediated chronic kidney diseases. Currently in Phase I of clinical trials, AZD2373 shows promise as a potential candidate for the future landscape of APOL1 mediated kidney diseases.
Key Takeaways:
- North America is expected to dominate the market while growing with a CAGR of 4.1% during the forecast period.
- The market in India is projected to witness a CAGR of 4.4% during the forecast period.
- The market in the United Kingdom is expected to grow at a 4.2% CAGR during the forecast period.
- By indication, chronic kidney disease is projected to lead the segment and is estimated to grow with a CAGR of 5.8% during the forecast period.
- The end-stage kidney disease segment is expected to grow with a CAGR of 2.1% throughout the forecast period.
"Increasing focus on research and development for understanding the underlying cause of APOL1 mediated kidney disease and developing targeted therapies is expected to drive market growth over the forecast period," - comments an analyst at FMI.
Ask our Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-12115
Competitive Landscape:
The APOL1 mediated kidney disease market is extremely competitive and consists of various key industry players. These players are heavily investing in the APOL1-mediated kidney disease treatment market.
The key industry players are Vertex Pharmaceuticals Incorporated, Ionis Pharmaceuticals, AstraZeneca, Pfizer Inc., Novartis AG, GlaxoSmithKline plc, Merck & Co., Inc., Sanofi S.A., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Roche Holding AG.
Some recent developments in the market are:
Key market players make use of organic growth strategies like acquisition, tie-ups, mergers, partnerships, and collaboration to enhance their product portfolio. This is expected to fuel the global APOL1-mediated kidney disease market.
- On November 4, 2022, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) collaborated with basketball Hall-of-Famer Alonzo Mourning to introduce "Power Forward," an educational initiative. This program aims to increase awareness of APOL1-mediated kidney disease (AMKD) and emphasize the significance of early diagnosis and genetic testing.
- In July 2022, AstraZeneca partnered with the Indian Society of Nephrology to establish the chronic kidney disease academy.
- On March 22, 2022, Vertex Pharmaceuticals Incorporated disclosed the advancement of VX-147 into pivotal development for individuals affected by proteinuric kidney disease caused by two mutations in the APOL1 gene (AMKD).
More Valuable Insights:
Future Market Insights offers an unbiased analysis of the global APOL1-mediated kidney disease market, providing historical data for 2017 to 2022 and forecast statistics from 2023 to 2033.
To understand opportunities in the APOL1-mediated kidney disease market, the market is segmented on the basis of indication and region.
For more Report Customization, connect with us at https://www.futuremarketinsights.com/customization-available/rep-gb-12115
Key Segments Profiled:
By Indication:
- Chronic Kidney Disease
- Focal segmental glomerulosclerosis (FSGS)
- Human immunodeficiency virus (HIV)-associated Nephropathy
- Hypertension-associated Kidney Disease
- End-Stage Kidney Disease
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Get an instant 20% discount on this report - Buy Now!
Table of Content (ToC):
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
View the Complete ToC of this Report with figures here @ https://www.futuremarketinsights.com/toc/rep-gb-12115
About the Packaging Division at Future Market Insights:
The healthcare team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with the objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.
Explore FMI's related ongoing Coverage in Healthcare Market Domain:
Fabry Disease Market Size: The global Fabry disease market size is worth US$ 1.9 Billion in 2022. The market is projected to witness a robust CAGR of 8% over the forecast period of 2022 to 2032, to arrive at a market valuation of US$ 4.10 Billion by 2032.
Rare Disease Clinical Trials Market Share: The rare disease clinical trials market size is projected to be valued at US$ 12,566.14 million in 2023 and is expected to rise to US$ 31,715.25 million by 2033. The sales of rare disease clinical trials are expected to record a significant CAGR of 9.7% during the forecast period.
Neurodegenerative Disease Market Growth:The neurodegenerative disease market is anticipated to register a CAGR of 7% during the forecast period, up from US$ 43.7 Billion in 2021 to reach a valuation of US$ 92 Billion by 2032.
Infectious Disease Diagnostics Market Opportunity: In 2022, the infectious disease diagnostics market is anticipated to be worth US$ 1.47 billion in terms of revenue. The market is projected to expand at a CAGR of 7% to reach a size of US$ 3.48 billion by 2032.
Autoimmune Disease Therapeutics Market Demand: The global autoimmune disease therapeutics market is likely to be valued at US$ 68,410.54 million in 2022 and is predicted to secure a moderate-paced CAGR of 5.6% during the forecast period. The market is expected to grow at a value of US$ 1,17,967.44 million by 2032.
About Future Market Insights (FMI):
Future Market Insights, Inc. (ESOMAR certified, Stevie Award - recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10 years.
Contact Us:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: [email protected]
Website: https://www.futuremarketinsights.com
LinkedIn | Twitter | Blogs
SOURCE: Future Market Insights, Inc.